{"id":"rosiglitazone-and-pegasys-ribavirin","safety":{"commonSideEffects":[{"rate":null,"effect":"Fluid retention and edema"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to enhance insulin sensitivity and reduce hepatic glucose production. Pegasys (peginterferon alfa-2a) combined with ribavirin provides antiviral activity against hepatitis C virus through interferon-mediated immune activation and ribavirin's direct antiviral effects. This combination addresses concurrent type 2 diabetes and chronic hepatitis C infection.","oneSentence":"This combination uses rosiglitazone to improve insulin sensitivity in diabetic patients while pegasys/ribavirin acts as an antiviral therapy for hepatitis C infection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:06:04.967Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus in patients with chronic hepatitis C infection"}]},"trialDetails":[{"nctId":"NCT00274495","phase":"PHASE4","title":"Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver","status":"TERMINATED","sponsor":"Beth Israel Medical Center","startDate":"2006-01","conditions":"Chronic Hepatitis C Infection, Fatty Liver","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rosiglitazone and Pegasys/Ribavirin","genericName":"Rosiglitazone and Pegasys/Ribavirin","companyName":"Beth Israel Medical Center","companyId":"beth-israel-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses rosiglitazone to improve insulin sensitivity in diabetic patients while pegasys/ribavirin acts as an antiviral therapy for hepatitis C infection. Used for Type 2 diabetes mellitus in patients with chronic hepatitis C infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}